Company · Healthtech & Bio

Gyala Therapeutics

gyalatx.com ↗ ·Barcelona ·Seed

Gyala Therapeutics is a Barcelona-based, clinical-stage biotech spun off in 2020 from Hospital Clínic Barcelona and IDIBAPS, developing CAR-T cell therapies for hematologic cancers. Its lead candidate, GYA01, is a first-in-class CAR-T targeting the CD84 antigen, now in a Phase I/IIa trial for relapsed/refractory acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). The company has raised roughly €11M to date from private investors plus Spanish public innovation grants (NEOTEC, CDTI).

Founded

2020

Founders

News

Rounds

Investors

SectorsBiotechnology, Cell Therapy, Oncology, Immunotherapy Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 1 Aug 2026

Founders

Claudio Santos

Co-Founder & Chief Executive Officer

Manel Juan

Co-Founder & Senior Scientific Advisor

Global models 5

Sana Biotechnology

United States · sana.com ↗

VC-backed clinical-stage cell therapy company engineering CAR-based and other cell therapies, one of the largest-ever private biotech venture raises before its 2021 IPO.

$700MComparable

Allogene Therapeutics

United States · www.allogene.com ↗

Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematologic and solid cancers, raised via record-setting Series A/B rounds pre-IPO.

$373MComparable

Century Therapeutics

United States · www.centurytx.com ↗

Clinical-stage biotech engineering iPSC-derived CAR-T/CAR-NK cell therapies for cancer, matching Gyala's cell-therapy-for-hematologic-malignancy model.

$250MComparable

Poseida Therapeutics

United States · poseida.com ↗

Clinical-stage biotech developing next-generation CAR-T therapies for hematologic malignancies using non-viral gene engineering, closely paralleling Gyala's approach.

$228MComparable

Autolus Therapeutics

United Kingdom · www.autolus.com ↗

European clinical-stage biotech (academic spin-out, like Gyala) developing programmed CAR-T cell therapies for leukemias and lymphomas.

$150MComparable

Investors 3

CDTI Innovación (Innvierte / SICC)

Funding rounds 4

Other · €3.7M

Gyala Therapeutics secured €3.7M in public funding from Spain's Ministry of Science, Innovation and Universities under the CPP 2024 programm…

2026-02-11

Seed · €3M

Gyala Therapeutics, a spin-off of Hospital Clínic de Barcelona and IDIBAPS, raised €3M from Invivo Partners, Nara Capital and CDTI Innvierte…

2025-09-16

Series A

CDTI Innovación announced, via its Innvierte programme, that it is entering the capital of Gyala Therapeutics alongside NARA Health Capital …

2024-10-15

Seed · €1.5M

Gyala Therapeutics, a spin-off of Hospital Clínic-IDIBAPS developing new CAR-T therapies for blood cancers, raised €1.5M in seed financing f…

2020-05-26

News & media 4

Published	Article
2026-02-10	Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options ↗ PR Newswire
2025-09-15	Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias ↗ PR Newswire
2025-09-15	Gyala Therapeutics Raises €3M in Funding ↗ FinSMEs
2020-05-26	A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS secures a 1.5 million-euro investment from Invivo Ventures ↗ Hospital Clínic Barcelona